Abstract
MCP-Mod (Multiple Comparison Procedure-Modelling) is an efficient statistical method for the analysis of Phase II dose-finding trials, although it requires specialised expertise to pre-specify plausible candidate models along with model parameters. This can be problematic given limited knowledge of the agent/compound being studied, and misspecification of candidate models and model parameters can severely degrade its performance. To circumvent this challenge, in the work, we introduce LiMAP-curvature, a Bayesian model-free approach for the detection of the dose-response signal in Phase II dose-finding trials. LiMAP-curvature is built upon a Bayesian hierarchical framework incorporating information about the total curvature of the dose-response curve. Through extensive simulations, we show that LiMAP-curvature has comparable performance to MCP-Mod if the true underlying dose-response model is included in the candidate model set of MCP-Mod. Otherwise, LiMAP-curvature can achieve performance superior to that of MCP-Mod, especially when the true dose-response model drastically deviates from candidate models in MCP-Mod.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Methodology description updated; author information updated; Supplemental files updated.
Data Availability
All data produced in the present work are simulated.